CTLA4 and colorectal carcinoma: This was chosen in view of the rapid initial clinical and serological response to pembrolizumab and the long-lasting clinical benefit seen with the combined blockade of PD-1 and CTLA-4 [14], which had just been approved for treatment of MSI-high CRC after failure of one line of chemotherapy [17].